Lab Assignment Sample

Yuxi Mao

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Abstract # | Title | Word Count | #Words (Verified by WordNet) | #Medical Words  (Verified by Bioportal / BioNLP)  All (Gene/Species/etc) |
| 1 | A randomised controlled trial of memory flexibility training (MemFlex) to enhance memory flexibility and reduce depressive symptomatology in individuals with major depressive disorder. | 225 | 103 | 0 |
| 2 | The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature. | 250 | 31 | 0 |
| 3 | Cognitive Impairment Along the Course of Depression: Non-Pharmacological Treatment Options. | 195 | 85 | 0 |
| 4 | Self-monitoring and personalized feedback based on the experiencing sampling method as a tool to boost depression treatment: a protocol of a pragmatic randomized controlled trial (ZELF-i). | 348 | 44 | 0 |
| 5 | Do comorbid social and other anxiety disorders predict outcomes during and after cognitive therapy for depression? | 251 | 18 | 0 |
| 6 | Asymptotic and exact interval estimators of the common odds ratio under the sequential parallel comparison design. | 159 | 82 | 0 |
| 7 | Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression? | 250 | 32 | 0 |
| 8 | Psychopharmacotherapy of obsessive-compulsive symptoms within the framework of Tourette syndrome. | 519 | 244 | 0 |
| 9 | Effect of collaborative depression treatment on risk for diabetes: A 9-year follow-up of the IMPACT randomized controlled trial. | 258 | 121 | 0 |
| 10 | Patient's experience with blended video- and internet based cognitive behavioural therapy service in routine care. | 400 | 44 | 0 |
|  |  |  |  |  |

Abstract 1

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 76 | navigation, memory, store, cognition, Impairment, flexibility, memory, retrieval, impact, health, phase, trial, N, potential, intervention, science, Memory, Flexibility, MemFlex, training, programme, memory, difficulties, symptoms, Disorder, MemFlex, Psychoeducation, intervention, range, effects, target, memory, flexibility, targets, symptoms, status, follow-up, effect, sizes, sample, size, trial, Results, effect, sizes, favour, MemFlex, memory, flexibility, d, p, loss, diagnosis, OR, p, outcome, days, d, p, effect, size, between-group, difference, symptoms, d, p, Effect, sizes, favour, MemFlex, trial, evaluation, MemFlex, avenue, treatment, depression, |
| POS:Verb | 21 | is, have, evaluated, drawn, sought, ameliorate, improve, was, compared, determine, be, used, estimate, demonstrated, expected, was, observed, suggest, be, warranted, improving, |
| NER : Name | 0 |  |
| Triplet | 97 | [(Successful navigation,is integral to,cognition,1.0), (navigation,is integral to,cognition,1.0), (Successful navigation,is,integral,1.0), (Successful navigation,is integral to,daily cognition,1.0), (navigation,is integral to,daily cognition,1.0), (navigation,is,integral,1.0)]  [(Impairment,can thereby have,detrimental impact on mental health,1.0), (Impairment,can have,impact on health,1.0), (Impairment,can have,detrimental impact,1.0), (Impairment,can have,impact on mental health,1.0), (Impairment,is in,flexibility of memory retrieval,1.0), (Impairment,can have,detrimental impact on mental health,1.0), (Impairment,can thereby have,impact,1.0), (Impairment,can thereby have,impact on mental health,1.0), (Impairment,can have,impact,1.0), (Impairment,can thereby have,detrimental impact on health,1.0), (Impairment,can have,detrimental impact on health,1.0), (Impairment,can thereby have,detrimental impact,1.0), (Impairment,can thereby have,impact on health,1.0)]  [(memory difficulties,improve,symptoms of Major Depressive Disorder,1.0), (memory difficulties,improve,symptoms,1.0), (improve,symptoms of,Major Depressive Disorder,0.4703948300210511), (improve,symptoms of,Depressive Disorder,0.4703948300210511), (improve,symptoms of,Disorder,0.4703948300210511), (memory difficulties,improve,symptoms of Depressive Disorder,1.0), (memory difficulties,improve,symptoms of Major Disorder,1.0), (memory difficulties,improve,symptoms of Disorder,1.0), (improve,symptoms of,Major Disorder,0.4703948300210511)]  [(MemFlex,targets of,depressive symptoms,1.0), (MemFlex,determine,likely range of effects on primary target of memory flexibility at post-intervention,1.0), (MemFlex,clinical targets of,self-reported depressive symptoms,1.0), (MemFlex,was compared,determine,0.04233298802032592), (MemFlex,determine,likely range of effects,1.0), (MemFlex,determine,likely range of effects on target of memory flexibility at post-intervention,1.0), (MemFlex,co-primary clinical targets of,self-reported symptoms,1.0), (MemFlex,clinical targets of,self-reported symptoms,1.0), (MemFlex,co-primary clinical targets of,symptoms,1.0), (MemFlex,co-primary clinical targets at,three-month follow-up,1.0), (MemFlex,determine,likely range of effects on primary cognitive target,1.0), (MemFlex,clinical targets of,symptoms,1.0), (MemFlex,determine,likely range of effects on cognitive target of memory flexibility at post-intervention,1.0), (MemFlex,co-primary targets of,depressive symptoms,1.0), (MemFlex,co-primary targets of,self-reported depressive symptoms,1.0), (MemFlex,co-primary clinical targets at,follow-up,1.0), (MemFlex,determine,likely range of effects on cognitive target at post-intervention,1.0), (MemFlex,determine,likely range of effects on cognitive target of memory flexibility,1.0), (MemFlex,co-primary targets at,three-month follow-up,1.0), (MemFlex,clinical targets at,three-month follow-up,1.0), (MemFlex,determine,likely range of effects on target at post-intervention,1.0), (MemFlex,determine,likely range of effects on primary target at post-intervention,1.0), (MemFlex,determine,likely range of effects on primary cognitive target at post-intervention,1.0), (MemFlex,determine,likely range,1.0), (MemFlex,targets of,self-reported symptoms,1.0), (MemFlex,targets at,follow-up,1.0), (MemFlex,co-primary targets of,symptoms,1.0), (MemFlex,determine,likely range of effects on target,1.0), (MemFlex,targets of,self-reported depressive symptoms,1.0), (MemFlex,co-primary clinical targets of,self-reported depressive symptoms,1.0), (MemFlex,co-primary targets at,follow-up,1.0), (MemFlex,co-primary clinical targets of,depressive symptoms,1.0), (MemFlex,co-primary targets of,self-reported symptoms,1.0), (MemFlex,determine,likely range of effects on primary cognitive target of memory flexibility,1.0), (MemFlex,determine,likely range of effects on primary cognitive target of memory flexibility at post-intervention,1.0), (MemFlex,targets of,symptoms,1.0), (MemFlex,clinical targets at,follow-up,1.0), (MemFlex,determine,likely range of effects on primary target of memory flexibility,1.0), (MemFlex,targets at,three-month follow-up,1.0), (MemFlex,clinical targets of,depressive symptoms,1.0), (MemFlex,determine,likely range of effects on target of memory flexibility,1.0), (MemFlex,was,compared,1.0), (MemFlex,determine,likely range of effects on primary target,1.0), (MemFlex,determine,likely range of effects on cognitive target,1.0)]  [(effect sizes,estimate sample size for,trial,1.0), (effect sizes,could,could used,1.0), (effect sizes,estimate sample size for,fully-powered trial,1.0), (effect sizes,could,could subsequently used,1.0), (effect sizes,estimate,sample size,1.0)] |

Abstract 2

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 20 | disorder, MDD, health, concern, depression, TRD, need, management, MDD, review, literature, burden, number, treatment, steps, TRD/non-response, MDD, episode, burden, TRD, |
| POS:Verb | 7 | is, represents, associated, increasing, was, performed, quantify, |
| NER : Name | 0 |  |
| Triplet | 51 | [(depressive disorder,is,global health concern,1.0), (Major disorder,is,public health concern,1.0), (disorder,is,global,1.0), (disorder,is,health concern,1.0), (Major depressive disorder,is,global health concern,1.0), (disorder,is,global health concern,1.0), (Major depressive disorder,is,health concern,1.0), (depressive disorder,is,health concern,1.0), (Major depressive disorder,is,public health concern,1.0), (Major disorder,is,health concern,1.0), (Major depressive disorder,is,global public health concern,1.0), (disorder,is,public health concern,1.0), (depressive disorder,is,public health concern,1.0), (Major disorder,is,global health concern,1.0), (disorder,is,public,1.0), (depressive disorder,is,global public health concern,1.0), (Major disorder,is,global public health concern,1.0), (disorder,is,global public health concern,1.0)]  [(treatment-resistant depression,represents,unmet need in management of MDD,1.0), (depression,represents,unmet need in management,1.0), (treatment-resistant depression,represents,unmet need in management,1.0), (depression,represents,need in management of MDD,1.0), (treatment-resistant depression,represents need In,particular,1.0), (depression,represents,unmet need,1.0), (depression,represents,key need,1.0), (depression,represents,need,1.0), (depression,represents,need in management,1.0), (treatment-resistant depression,represents,key unmet need,1.0), (treatment-resistant depression,represents,unmet need,1.0), (treatment-resistant depression,represents,need,1.0), (depression,represents need In,particular,1.0), (depression,represents,unmet need in management of MDD,1.0), (treatment-resistant depression,represents,key need in management of MDD,1.0), (depression,represents,key unmet need in management,1.0), (depression,represents,key need in management of MDD,1.0), (treatment-resistant depression,represents,key need,1.0), (depression,represents,key unmet need in management of MDD,1.0), (treatment-resistant depression,represents,need in management,1.0), (treatment-resistant depression,represents,need in management of MDD,1.0), (treatment-resistant depression,represents,key unmet need in management of MDD,1.0), (depression,represents,key need in management,1.0), (depression,represents,key unmet need,1.0), (treatment-resistant depression,represents,key need in management,1.0), (key unmet need,is in,management of MDD,1.0), (treatment-resistant depression,represents,key unmet need in management,1.0)]  [(review,quantify,burden,1.0), (systematic review,quantify,burden,1.0), (review,quantify,burden of TRD,1.0), (systematic review,was,performed,1.0), (systematic review,quantify,burden of TRD,1.0), (review,was,performed,1.0)] |

Abstract 3

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 62 | Disorder, MDD, disorders, impact, society, review, deficits, states, depression, effect, impairment, CI, recovery, role, variables, development, CI, MDD, patients, evidence, CI, depression, research, treatment, options, patient, group, aim, review, interventions, CI, MDD, patients, remediation, therapy, CRT, exercise, yoga, therapy, neuromodulation, approaches, neurostimulation, neurofeedback, training, conclusion, directions, research, CI, depression, designs, comparison, treatment, approaches, neurocognition, outcome, MDD, effects, CRT, treatment, approaches, intervention, programs, |
| POS:Verb | 22 | is, summarize, outline, discuss, is, cumulating, regarding, is, is, are, thought, reduce, affected, discuss, propose, Looking, suggest, include, be, examined, compared, create, |
| NER : Name | 0 |  |
| Triplet | 90 | [(we,summarize,deficits,1.0), (we,summarize,neurocognitive deficits,1.0), (we,summarize deficits In,review,1.0), (we,summarize deficits In,narrative review,1.0), (we,summarize deficits during,acute,1.0)]  [(we,Furthermore outline,potential effect of impairment on recovery,1.0), (we,Furthermore outline,potential effect of cognitive impairment on functional recovery,1.0), (we,outline,potential negative effect of impairment,1.0), (we,discuss,role of variables in development of CI for MDD patients,1.0), (we,outline,potential negative effect of impairment on functional recovery,1.0), (discuss,role in,development of CI for MDD patients,0.9583791811028466), (we,outline,potential effect of impairment,1.0), (we,discuss,role in development for MDD patients,1.0), (we,discuss,role of variables in development,1.0), (we,outline,potential negative effect of impairment on recovery,1.0), (we,Furthermore outline,potential negative effect of impairment,1.0), (we,outline,potential effect on recovery,1.0), (we,discuss,role of several variables,1.0), (we,outline,potential negative effect on recovery,1.0), (we,Furthermore outline,potential effect of cognitive impairment,1.0), (we,outline,potential negative effect on functional recovery,1.0), (we,outline,potential negative effect of cognitive impairment on functional recovery,1.0), (we,Furthermore outline,potential effect on recovery,1.0), (we,outline,potential effect on functional recovery,1.0), (we,Furthermore outline,potential effect on functional recovery,1.0), (we,Furthermore outline,potential effect of impairment on functional recovery,1.0), (we,discuss,role of several variables in development for MDD patients,1.0), (we,Furthermore outline,potential negative effect of impairment on recovery,1.0), (we,outline,potential negative effect,1.0), (discuss,role in,development for MDD patients,0.9583791811028466), (we,Furthermore outline,potential effect,1.0), (we,Furthermore outline,potential negative effect on functional recovery,1.0), (discuss,role of,several variables,0.9583791811028466), (we,discuss,role of several variables in development of CI,1.0), (we,discuss,role of several variables in development of CI for MDD patients,1.0), (role,is in,development of CI for MDD patients,1.0), (we,Furthermore outline,potential effect of cognitive impairment on recovery,1.0), (we,outline,potential effect of cognitive impairment on functional recovery,1.0), (we,discuss,role in development of CI,1.0), (discuss,role in,development,0.9583791811028466), (we,Furthermore outline,potential negative effect of cognitive impairment on functional recovery,1.0), (we,Furthermore outline,potential negative effect of cognitive impairment on recovery,1.0), (discuss,role of,variables,0.9583791811028466), (we,outline,potential negative effect of cognitive impairment on recovery,1.0), (we,discuss,role of variables in development of CI,1.0), (we,outline,potential effect of cognitive impairment,1.0), (we,outline,potential effect of impairment on functional recovery,1.0), (discuss,role in,development of CI,0.9583791811028466), (we,Furthermore outline,potential negative effect of impairment on functional recovery,1.0), (we,Furthermore outline,potential negative effect of cognitive impairment,1.0), (we,outline,potential effect of impairment on recovery,1.0), (we,outline,potential effect,1.0), (we,discuss,role in development of CI for MDD patients,1.0), (we,discuss,role of several variables in development,1.0), (we,discuss,role,1.0), (we,outline,potential effect of cognitive impairment on recovery,1.0), (we,Furthermore outline,potential negative effect on recovery,1.0), (we,discuss,role in development,1.0), (we,discuss,role of variables in development for MDD patients,1.0), (we,Furthermore outline,potential negative effect,1.0), (we,discuss,role of variables,1.0), (we,Furthermore outline,potential effect of impairment,1.0), (we,outline,potential negative effect of cognitive impairment,1.0)]  [(cumulating evidence,is,still scarce,1.0), (persistent CI,is in,unipolar depression,1.0), (persistent CI,research on,treatment options specific for patient group,1.0), (cumulating evidence,is,scarce,1.0)]  [] |

Abstract 4

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 30 | Depression, cause, disability, burden, quality, life, patients, treatments, depression, need, interventions, self-management, patients, self-monitoring, feedback, Experience, Method, ESM, intervention, treatment, outcomes, aim, study, efficacy, self-monitoring, feedback, tool, treatment, complaints, setting, |
| POS:Verb | 17 | is, leading, reduce, improve, need, be, optimized, is, reinforce, personalized, Sampling, provide, empowering, enhances, is, investigate, personalized, |
| NER : Name | 0 |  |
| Triplet | 48 | [(Depression,is,leading cause,1.0), (Depression,is cause worldwide of,disability,1.0), (Depression,is leading cause worldwide of,disability,1.0), (Depression,is cause of,disability,1.0), (Depression,is,leading cause worldwide,1.0), (Depression,is,leading,1.0), (Depression,is,cause worldwide,1.0), (Depression,is,cause,1.0), (Depression,is leading cause of,disability,1.0)]  [(burden,improve,quality of life,1.0), (societal burden,improve,quality of life,1.0), (societal burden,improve quality for,individual patients,1.0), (societal burden,improve,quality,1.0), (societal burden,improve quality for,patients,1.0), (burden,improve,quality,1.0), (burden,improve quality for,patients,1.0), (burden,improve quality for,individual patients,1.0)]  []  [(Experience,could provide,such person-tailored,0.7289583882102222), (Experience,Sampling,ESM,0.6906166878582499), (Experience,Sampling,Method,0.6906166878582499), (Experience,could provide,person-tailored,0.7289583882102222)]  [(efficacy,personalized feedback as,add-on tool,1.0), (add-on tool,is in,treatment of depressive complaints,1.0), (efficacy,personalized feedback as,tool in treatment of depressive complaints in setting,1.0), (efficacy,personalized feedback as,tool in treatment in natural setting,1.0), (aim,investigate,efficacy of self-monitoring,1.0), (efficacy,personalized feedback as,tool in treatment in setting,1.0), (efficacy,personalized feedback as,add-on tool in treatment of depressive complaints in natural setting,1.0), (efficacy,personalized feedback as,tool in treatment,1.0), (efficacy,personalized feedback as,add-on tool in treatment of depressive complaints in setting,1.0), (efficacy,personalized feedback as,tool in treatment of depressive complaints,1.0), (efficacy,personalized feedback as,add-on tool in treatment of depressive complaints,1.0), (efficacy,personalized feedback as,add-on tool in treatment in natural setting,1.0), (efficacy,personalized feedback as,add-on tool in treatment of complaints in setting,1.0), (efficacy,personalized feedback as,tool in treatment of complaints,1.0), (primary aim,investigate,efficacy,1.0), (efficacy,personalized feedback as,add-on tool in treatment of complaints,1.0), (treatment,is in,natural setting,1.0), (efficacy,personalized feedback as,tool in treatment of complaints in natural setting,1.0), (efficacy,personalized feedback as,tool in treatment of depressive complaints in natural setting,1.0), (efficacy,personalized feedback as,tool,1.0), (efficacy,personalized feedback as,add-on tool in treatment in setting,1.0), (efficacy,personalized feedback as,tool in treatment of complaints in setting,1.0), (efficacy,personalized,feedback,1.0), (aim,investigate,efficacy,1.0), (primary aim,investigate,efficacy of self-monitoring,1.0), (efficacy,personalized feedback as,add-on tool in treatment,1.0), (efficacy,personalized feedback as,add-on tool in treatment of complaints in natural setting,1.0)] |

Abstract 5

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 20 | therapy, CT, symptoms, adults, disorder, MDD, comorbid, anxiety, disorder, type, anxiety, outcomes, study, CT, outcomes, adults, MDD, comorbid, anxiety, disorders, |
| POS:Verb | 3 | improves, influence, compared, |
| NER : Name | 0 |  |
| Triplet | 3 | [(symptoms,is in,adults with major depressive disorder,1.0), (adults,is with,major depressive disorder,1.0)]  [(adults,is with,MDD,1.0)] |

Abstract 6

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 53 | treatments, diseases, trial, use, parallel, comparison, design, number, patients, reduction, placebo, response, rate, assumption, odds, ratio, responses, phases, parallel, comparison, design, maximum, likelihood, estimator, odds, ratio, basis, likelihood, interval, interval, estimators, odds, ratio, responses, Monte, Carlo, simulation, performance, estimators, variety, situations, interval, interval, estimators, study, efficacy, dose, aripiprazole, therapy, patients, disorder, use, estimators, |
| POS:Verb | 16 | studying, consider, reduce, needed, is, derive, derive, employ, evaluate, find, developed, perform, use, assessing, treating, illustrate, |
| NER : Name | 0 |  |
| Triplet | 46 | [(we,studying,treatments,1.0), (we,studying,treatments for diseases,1.0), (we,studying treatments in,trial,1.0), (we,studying,treatments for psychiatric diseases,1.0), (we,studying treatments in,placebo-controlled trial,1.0)]  [(we,derive,conditional maximum likelihood estimator for odds ratio,1.0), (we,derive maximum likelihood estimator Under,assumption,1.0), (we,derive,maximum likelihood estimator,1.0), (odds ratio,is constant between,phases in parallel comparison design,1.0), (we,derive,maximum likelihood estimator for odds ratio,1.0), (phases,is in,sequential parallel comparison design,1.0), (odds ratio,is constant between,phases in sequential parallel comparison design,1.0), (odds ratio,is constant between,phases,1.0), (odds ratio,is,constant,1.0), (we,derive,conditional maximum likelihood estimator,1.0)]  [(we,further derive,interval estimators for odds ratio,1.0), (we,further derive,three asymptotic interval,1.0), (we,further derive interval estimators On,basis of conditional likelihood,1.0), (we,further derive,interval estimators for odds ratio of responses,1.0), (we,derive interval estimators On,basis of conditional likelihood,1.0), (we,further derive,exact interval estimators,1.0), (we,derive,exact interval estimators for odds ratio of responses,1.0), (we,further derive,exact interval estimators for odds ratio of responses,1.0), (we,further derive,interval estimators,1.0), (we,further derive interval estimators On,basis,1.0), (we,derive,interval estimators,1.0), (we,derive,interval estimators for odds ratio of responses,1.0), (we,derive interval estimators On,basis,1.0), (we,derive interval estimators On,basis of likelihood,1.0), (we,derive,exact interval estimators for odds ratio,1.0), (we,derive,interval estimators for odds ratio,1.0), (we,further derive interval estimators On,basis of likelihood,1.0), (we,further derive,three interval,1.0), (we,derive,three asymptotic interval,1.0), (we,further derive,exact interval estimators for odds ratio,1.0), (we,derive,three interval,1.0), (we,derive,exact interval estimators,1.0)]  [(We,employ,Monte Carlo simulation,1.0), (We,evaluate,performance of estimators,1.0), (We,evaluate,performance,1.0), (We,evaluate,performance of interval estimators,1.0)]  []  [(We,use,study,1.0), (We,use,placebo-controlled study,1.0), (We,use,double-blind study,1.0), (patients,is with,major depressive disorder,1.0), (We,use,double-blind placebo-controlled study,1.0)] |

Abstract 7

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 24 | trials, buprenorphine, BUP, treatment, disorder, MDD, results, utility, risk, abuse, dependence, BUP, samidorphan, SAM, mechanism, properties, properties, objective, article, results, BUP/SAM, trials, treatment, MDD, |
| POS:Verb | 12 | have, displayed, was, limited, combining, is, negated, reduces, allowing, remain, is, analyze, |
| NER : Name | 0 |  |
| Triplet | 32 | [(its clinical utility,was,limited,1.0), (its utility,was limited by,risk,1.0), (Past trials,is in,treatment of major depressive disorder,1.0), (Past trials,have displayed results,limited by risk,1.0), (its clinical utility,was limited by,risk of abuse,1.0), (Past trials,have displayed,results,1.0), (its clinical utility,was limited by,risk,1.0), (its utility,was limited by,risk of abuse,1.0), (Past trials,have displayed results,limited by risk of abuse,1.0), (Past trials,have displayed,favorable results,1.0), (its utility,was,limited,1.0), (Past trials,have displayed results,limited,1.0)]  [(euphoric high,combining,BUP,1.0), (euphoric high,combining BUP with,SAM,1.0), (euphoric high,is,negated,1.0), (high,combining BUP with,samidorphan,1.0), (high,is,negated,1.0), (euphoric high,combining BUP with,samidorphan,1.0), (high,combining BUP with,SAM,1.0), (high,combining,BUP,1.0)]  [(objective,analyze,results of BUP/SAM clinical trials,1.0), (objective,analyze,results of BUP/SAM trials,1.0), (objective,analyze,results,1.0), (objective,analyze results as,treatment,1.0), (objective,analyze results as,adjunctive treatment for treatment-resistant MDD,1.0), (objective,analyze results as,treatment for MDD,1.0), (objective,analyze results as,adjunctive treatment,1.0), (objective,analyze results as,treatment for treatment-resistant MDD,1.0), (objective,analyze,results of BUP/SAM premarketing clinical trials,1.0), (objective,is As,such,1.0), (objective,analyze results as,adjunctive treatment for MDD,1.0), (objective,analyze,results of BUP/SAM premarketing trials,1.0)] |

Abstract 8

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 178 | Therapy, BT, step, treatment, OCD, TS, medication, augmentation, situations, family, preference, BT, priority, review, complexity, drug, treatment, patients, disorder, OCD, Tourette, syndrome, TS, problems, OCD, TS, combination, detail, disorders, wax, time, courses, necessities, options, treatment, subtypes, OCD, symptoms, OCS, tics, OCS, TS, %, tics, OCD, %, phenomena, feelings, psychopathologies, hyperactivity, disorder, ADHD, mood, problems, anxiety, hair, disorder, skin, disorder, OCD, TS, assessment, drug, treatment, problems, experience, planning, evaluation/adaptation, Drugs, symptoms, disorders, parallel, right, OCD, serotonin, reuptake, inhibitors, SSRI, TS, tics, antipsychotics, cases, OCD, tics, OCS, augmentation, antipsychotics, aripiprazole, risperidone, OCS, tics, benzamide, sulpiride, antipsychotics, combination, OCS, tics, problems, psychopathologies, OCD, effectiveness, SSRI, OCS, hand, cases, OCD, tics, SSRI, OCS, stress, sensitivity, problems, abilities, suppression, sum, guidance, uncertainties, data, base, psychopharmacotherapy, OCD, TS, quality, primer, Tourette, Syndrome, TS, overview, aspects, disorder, suggestion, Behavior, Therapy, BT, treatment, OCS/OCD, TS, BT, OCD, patients, BT, intervention, situation, medication, play, augmentation, drug, treatment, priority, BT, family, relationship, symptoms, OCS, TS, review, issue, essentials, core, aspects, TS, symptoms/disorder, OCS/OCD, comorbidities, TS, levels, investigation, psychopathology, pathophysiology, burden, meanings, treatment, drugs, use, treatment, OCS/OCD, framework, TS, |
| POS:Verb | 67 | be, recommended, be, added, reverse, is, given, comorbid, is, overlapping, wane, have, are, are, associated, urges, reflect, overlap, are, pulling, picking, are, needs, are, reduce, cure, be, treated, be, prescribed, respond, recommended, improve, be, treating, attenuate, reduce, leading, improve, be, given, remain, has, been, published, giving, includes, be, recommended, seems, be, remain, comes, be, given, is, preferred, Concerning, broaden, starting, presenting, are, mentioned, are, discussed, are, explored, |
| NER : Name | 0 |  |
| Triplet | 184 | [(subtypes,are,questionable,1.0), (Distinct subtypes,are,questionable,1.0)]  [(tics,is in,OCD,1.0), (Obsessive-compulsive symptoms,are,frequently associated,1.0), (OCS,is in,TS,1.0), (symptoms,are,associated,1.0), (Obsessive-compulsive symptoms,are,associated,1.0), (symptoms,are,frequently associated,1.0)]  []  [(main additional psychopathologies,are,hyperactivity disorder,1.0), (additional psychopathologies,are,hyperactivity disorder,1.0), (additional psychopathologies,are,attention-deficit hyperactivity disorder,1.0), (main psychopathologies,are,hyperactivity disorder,1.0), (psychopathologies,are,hyperactivity disorder,1.0), (main additional psychopathologies,are,attention-deficit hyperactivity disorder,1.0), (psychopathologies,are,attention-deficit hyperactivity disorder,1.0), (main psychopathologies,are,attention-deficit hyperactivity disorder,1.0)]  [(hair disorder,Also are related to,OCD,1.0), (hair disorder,are,Also related to OCD with TS,1.0), (hair pulling disorder,are related to,OCD,1.0), (hair disorder,are,related,1.0), (hair pulling disorder,are,Also related to OCD with TS,1.0), (skin,Also are related to,OCD with TS,1.0), (skin,are,related,1.0), (hair disorder,are,Also related,1.0), (skin,picking,disorder,0.6906166878582499), (hair pulling disorder,are,Also related to OCD,1.0), (OCD,is with,TS,1.0), (hair pulling disorder,Also are related to,OCD,1.0), (hair disorder,are,related to OCD,1.0), (hair disorder,Also are related to,OCD with TS,1.0), (hair pulling disorder,are,related to OCD,1.0), (hair disorder,are,related to OCD with TS,1.0), (hair pulling disorder,are,related to OCD with TS,1.0), (hair pulling disorder,Also are related to,OCD with TS,1.0), (skin,Also are related to,OCD,1.0), (skin,are related to,OCD,1.0), (hair disorder,are,Also related to OCD,1.0), (skin,are related to,OCD with TS,1.0), (skin,are,Also related,1.0), (hair pulling disorder,are related to,OCD with TS,1.0), (hair disorder,are related to,OCD,1.0), (hair disorder,are related to,OCD with TS,1.0), (hair pulling disorder,are,Also related,1.0), (hair pulling disorder,are,related,1.0)]  [(drug treatment,Hence needs,high clinical experience,1.0), (drug treatment,needs,careful planning,1.0), (drug treatment,needs,experience,1.0), (drug treatment,needs,clinical experience,1.0), (drug treatment,needs,ongoing evaluation/adaptation,1.0), (drug treatment,Hence needs,careful planning,1.0), (drug treatment,needs,evaluation/adaptation,1.0), (drug treatment,needs,high clinical experience,1.0), (drug treatment,Hence needs,experience,1.0), (drug treatment,needs,high experience,1.0), (drug treatment,Hence needs,clinical experience,1.0), (drug treatment,Hence needs,planning,1.0), (drug treatment,Hence needs,ongoing evaluation/adaptation,1.0), (drug treatment,needs,planning,1.0), (drug treatment,Hence needs,high experience,1.0), (drug treatment,Hence needs,evaluation/adaptation,1.0)]  [(Drugs,reduce,clinical symptoms,1.0), (Drugs,reduce,symptoms,1.0)]  [(augmentation,is with,antipsychotics,1.0), (OCD,is with,tics,1.0), (augmentation,may improve OCS In,cases of OCD,1.0), (augmentation,may improve,OCS,1.0), (augmentation,may improve,tics,1.0), (augmentation,may improve tics In,cases,1.0), (augmentation,may improve tics In,cases of OCD,1.0), (augmentation,may improve OCS In,cases of OCD with tics,1.0), (augmentation,may improve tics In,cases of OCD with tics,1.0), (augmentation,may improve OCS In,cases,1.0)]  [(benzamide sulpiride,may,Also may beneficial,1.0), (benzamide sulpiride,treating,combination of OCS,1.0), (benzamide sulpiride,may,may beneficial,1.0), (benzamide sulpiride,treating,combination,1.0)]  [(OCD,is with,tics,1.0), (other hand,is in,cases of OCD with tics,1.0)]  [(OCD,is with,TS,1.0), (scarce data base,is in,OCD with TS,1.0)]  [(high quality primer,giving,overview,1.0), (quality primer,has,has published,1.0), (high quality primer,has,Recently has published,1.0), (quality primer,giving,overview,1.0), (high quality primer,giving,timely overview,1.0), (quality primer,has,Recently has published,1.0), (quality primer,giving,timely overview,1.0), (high quality primer,has,has published,1.0)]  [(Behavior Therapy,be recommended for,treatment,1.0), (Behavior Therapy,be,recommended,1.0), (Behavior Therapy,be recommended for,treatment of OCS/OCD,1.0)]  [(BT,seems,equally effective,1.0), (BT,seems,effective,1.0), (BT,seems,effective for OCD,1.0), (BT,seems,effective for pure OCD,1.0), (BT,seems,equally effective for pure OCD,1.0), (BT,seems,equally effective for OCD,1.0)]  [(many patients,remain after,BT intervention,1.0), (many patients,remain,symptomatic,1.0), (patients,remain,symptomatic,1.0), (patients,remain after,BT intervention,1.0)]  [(medication,comes In,situation,1.0), (medication,comes into,play,1.0), (medication,comes into,play for augmentation,1.0)]  []  [(comorbidities,is with,TS,1.0), (issue,Concerning,important relationship between obsessive-compulsive symptoms,1.0), (issue,Concerning,relationship,1.0), (issue,Concerning,practically important relationship between symptoms,1.0), (issue,Concerning,important relationship,1.0), (issue,Concerning,relationship between symptoms,1.0), (issue,Concerning,important relationship between symptoms,1.0), (issue,Concerning,relationship between obsessive-compulsive symptoms,1.0), (issue,Concerning,practically important relationship between obsessive-compulsive symptoms,1.0), (issue,Concerning,practically important relationship,1.0)]  [(levels,are,mentioned,1.0), (their meanings,are,discussed,0.8720920184114438), (their specific meanings,are,discussed,0.8720920184114438), (Several levels,are,mentioned,1.0)] |

Abstract 9

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 101 | evidence, mechanisms, depression, risk, factor, diabetes, diabetes, risk, individuals, conditions, causes, death, disability, study, diabetes, outcomes, patients, risk, diabetes, question, depression, treatment, diabetes, onset, effect, care, program, depression, diabetes, incidence, adults, diabetes, Participants, care, patients, M, SD, age, years, %, disorder, diabetes, Indiana, sites, Improving, Access, Collaborative, Treatment, IMPACT, trial, Incident, diabetes, cases, diabetes, diagnoses, laboratory, values, diabetes, medication, prescription, record, Medicare/Medicaid, data, rate, incident, diabetes, care, group, %, %, care, group, care, group, reductions, symptom, severity, p, HR, %, CI, p, HR, %, CI, p, Cox, hazards, models, risk, incident, diabetes, treatment, groups, findings, possibility, depression, treatment, diabetes, risk, adults, |
| POS:Verb | 29 | suggest, is, reducing, is, given, are, leading, has, examined, prevents, delays, remains, examined, were, enrolled, were, defined, were, identified, using, was, exhibited, adjusted, indicated, did, differ, raise, be, reduce |
| NER : Name | 0 |  |
| Triplet | 1052 | [(collaborative care group,reductions in,depressive symptom severity,0.6686994492116972), (p,=,.024,1.0), (collaborative care group,reductions in,symptom severity,0.6686994492116972), (care group,greater reductions in,symptom severity,0.6686994492116972), (care group,reductions in,depressive symptom severity,0.6686994492116972), (care group,greater reductions in,depressive symptom severity,0.6686994492116972), (care group,reductions in,symptom severity,0.6686994492116972), (collaborative care group,greater reductions in,symptom severity,0.6686994492116972), (greater reductions,is in,depressive symptom severity,1.0), (collaborative care group,greater reductions in,depressive symptom severity,0.6686994492116972)]  [(depression treatment,reduce,excess diabetes risk of adults,1.0), (depression treatment,reduce,diabetes risk of depressed adults,1.0), (depression treatment,reduce,excess diabetes risk of depressed adults,1.0), (Our findings,raise,possibility,1.0), (Our novel findings,raise,possibility,1.0), (depression treatment,be,insufficient,1.0), (Our preliminary findings,raise,possibility,1.0), (depression treatment,reduce,excess diabetes risk of depressed older adults,1.0), (depression treatment,reduce,diabetes risk,1.0), (depression treatment,reduce,excess diabetes risk,1.0), (depression treatment,reduce,diabetes risk of adults,1.0), (depression treatment,reduce,diabetes risk of older adults,1.0), (depression treatment,reduce,excess diabetes risk of older adults,1.0), (depression treatment,reduce,diabetes risk of depressed older adults,1.0), (Our novel preliminary findings,raise,possibility,1.0)]and so on |

Abstract 10

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 20 | self-help, CBT, treatment, depression, approaches, treatment, option, patients, treatment, self-help, psychotherapy, disadvantages, approaches, advantages, focus, patient, empowerment, resource, use, treatment, |
| POS:Verb | 12 | guided, have, shown, be, be, blends, guided, reduce, maintaining, being, provide, compared, |
| NER : Name | 0 |  |
| Triplet | 10 | [(advantages,being,location-independent,0.9960192330429476), (major advantages,being,location-independent,0.9960192330429476)]  [(it,could provide,stronger focus,1.0), (it,Additionally could provide,stronger focus on patient empowerment,1.0), (it,could provide,focus on patient empowerment,1.0), (it,could provide,stronger focus on patient empowerment,1.0), (it,Additionally could provide,focus on patient empowerment,1.0), (it,could provide,focus,1.0), (it,Additionally could provide,focus,1.0), (it,Additionally could provide,stronger focus,1.0)] |